Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Diagnos Inc. has closed a non-brokered private placement of 8,333,333 units issued at a price of 30 cents per unit for gross proceeds of $2,499,999.90.

Each unit consists of:

• One common share;
• One common share warrant.

As part of the closing of the private placement, 8,333,333 warrants have been issued to the subscribers. Each warrant can be exercised to purchase one share at a price of 40 cents per share for a period of 18 months ending March 20, 2026.

The net proceeds from the private placement will be used to finance product development and commercialization of artificial-intelligence-based screening services, as well as general and administrative operations.

All securities issued as part of the private placement are subject to a statutory hold period ending Jan. 21, 2025.

The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

Diagnos would like to express its gratitude to the family office that participated in the private placement.

Diagnos is also providing the following clarification: The first paragraph of Section 6 of the 2024 management information circular, dated Aug. 21, 2024, should read as follows.

"The board of the corporation has set Aug. 21, 2024, as the record date for the determination of the registered holders of voting shares entitled to receive notice of the meeting. All holders of common shares as of the record date are entitled to attend and vote thereat in person or by proxy. As at Aug. 21, 2024, 81,435,607 common shares of the corporation were issued and outstanding. The common shares are the only securities outstanding and entitled to be voted at the meeting. Each common share entitles the holder thereof to one vote."

All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.